CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

Targeted Therapy to Resensitize Tumors to Radioactive Iodine

Published: Mon, 19 Nov 2018 12:00:00 EST
How might targeted therapy help patients with advanced thyroid cancer that has become radioactive iodine refractory?
Journal of Clinical Endocrinology & Metabolism

TNM Staging 8th Edition and Its Implications for Skin Cancer

Published: Mon, 19 Nov 2018 12:00:00 EST
This article summarizes important changes in the 8th edition of TNM that impact the staging, risk stratification, and management of melanoma and nonmelanoma skin cancer.
The British Journal of Dermatology

Multimodal General Anesthesia: Theory and Practice

Published: Mon, 19 Nov 2018 12:00:00 EST
The authors propose a novel strategy for multimodal general anesthesia predicated on choosing a combination of agents that act on different targets in the nociceptive system.
Anesthesia & Analgesia
Displaying results 4-6 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

AstraZeneca’s Mystic OS analysis paints tremelimumab as a dud in NSCLC

Published: Fri, 16 Nov 2018 10:51:54 +0000
Overall survival data from AstraZeneca’s phase 3 Mystic trial have cast more doubts on the prospects of anti-CTLA4 antibody tremelimumab. The readout suggests that, if anything, adding tremelimumab to PD-L1 drug Imfinzi results in worse outcomes in metastatic non-small cell lung cancer (NSCLC).

Chutes & Ladders—Dermavant hires Todd Zavodnick as CEO

Published: Thu, 15 Nov 2018 16:06:19 +0000
Dermavant has hired Todd Zavodnick as CEO; Bayer VP Alan Westwood will lead antimicrobial firm Matoke Pharma; Genentech I-O leader Wei Lin will head up Nektar's oncology work; and Google is bringing on Geisinger’s CEO to direct its healthcare efforts. Those moves plus more hirings, firings and retirings throughout the industry.

Boehringer Ingelheim and Epizyme launch $300M precision oncology program

Published: Thu, 15 Nov 2018 13:54:55 +0000
In a worldwide collaboration worth up to $300 million or more, Boehringer Ingelheim is expanding its precision oncology programs by tapping Epizyme for research into two previously unaddressed regulators of genes linked to cancer.
Displaying results 4-6 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code
1-800-4-the-clinx

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top